MSL
SGMO

Mackay Shields LLC’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Mackay Shields LLC’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-77,049
Closed -$966K – 1228
2021
Q1 		$966K Sell
77,049
-60,733
-44% -$818K 0.01% 1007
2020
Q4 		$2.15M Buy
137,782
+8,900
+7% +$104K 0.01% 827
2020
Q3 		$1.22M Sell
128,882
-19,700
-13% -$213K 0.01% 964
2020
Q2 		$1.33M Buy
148,582
+6,900
+5% +$64K 0.01% 925
2020
Q1 		$902K Buy
141,682
+26,400
+23% +$196K 0.01% 982
2019
Q4 		$965K Buy
115,282
+9,100
+9% +$83.7K 0.01% 1074
2019
Q3 		$961K Sell
106,182
-7,200
-6% -$80.8K 0.01% 1120
2019
Q2 		$1.22M Buy
113,382
+72,733
+179% +$774K 0.01% 1073
2019
Q1 		$388K Buy
40,649
+1,300
+3% +$13.3K ﹤0.01% 1231
2018
Q4 		$452K Sell
39,349
-4,151
-10% -$51.6K ﹤0.01% 1171
2018
Q3 		$737K Buy
43,500
+9,800
+29% +$149K 0.01% 936
2018
Q2 		$478K Hold
33,700
– – ﹤0.01% 1105
2018
Q1 		$640K Buy
+33,700
New +$720K ﹤0.01% 1076

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mackay Shields LLC's SGMO Position: Q2 2021 in Review

Mackay Shields LLC sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2021, closing a stake of 77,049 shares — an estimated $966K sold.

Mackay Shields LLC first reported a position in SGMO in Q1 2018 and held it in 13 quarters. The position peaked at $2.15M in Q4 2020. 197 funds tracked by Wall St. Rank hold SGMO as of Q2 2021.

  • Mackay Shields LLC reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 77,049 SANGAMO THERAPEUTICS INC shares in Q2 2021, an estimated $966K.
  • Mackay Shields LLC first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 13 quarters.
  • Mackay Shields LLC's SANGAMO THERAPEUTICS INC position peaked at $2.15M in Q4 2020.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.